Categories: Uncategorized

New opportunity for discovery of highly differentiated therapeutics for Alzheimer’s & Parkinson’s diseases announced

Cellectricon AB, a collaborative research organization dedicated to advancing drug discovery and research in the areas of chronic pain and CNS diseases, today announced the launch of a novel assay platform for in vitro neurodegenerative disease research. The platform, based on a patent-pending microfluidics technology, has been developed over the past two years in collaboration with a leading pharmaceutical company.

“The propagation of neurodegenerative disease associated peptides (NDAPs), such as tau and alpha-synuclein, within the brain is considered to be one of the major pathological mechanisms in progressive neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease”, said Dr. Sebastian Illes, Director of CNS Research at Cellectricon.  “With our new platform, we can model these neuropathological processes and we have the capacity and robustness to allow screening and profiling of larger compound sets in the search for molecules preventing prion-like spreading of NDAPs in neuronal circuits. We believe this will provide many new opportunities for the development of highly differentiated therapeutics for several neurodegenerative diseases.”

Cellectricon has successfully supported pharmaceutical companies and academic institutions for over five years with assay development, screening and preclinical compound validation for their pain and CNS disease projects. With the launch of its new assay platform, Cellectricon has significantly expanded the research opportunities available to customers working on progressive neurodegenerative diseases.

“We are extremely pleased to add this assay platform to our portfolio as it enables us to extend our services offering to encompass neurodegenerative disease research”, said Dr Mattias Karlsson, Cellectricon’s CEO. “With our new and patent-pending assay platform, we can create highly relevant, complex disease models and innovative assays for functional and morphological screening, and we are looking forward to discussing the new research possibilities that it opens up with delegates at Neuroscience in San Diego.”

L Finnsson

Recent Posts

Pipar\TBWA Named Advertising Agency of the Year for the Second Consecutive Year

Reykjavík, Iceland, 13.03.2025 - PiparTBWA has been named Advertising Agency of the Year for the…

3 weeks ago

QUIRKY CAMPERS UNVEILS DEDICATED GLASTONBURY 2025 CAMPERVAN FLEET

London, UK – March 12, 2025 – Quirky Campers, the UK's leading platform for handcrafted…

3 weeks ago

eXo Platform Unveils Version 7.0: A Game-Changer for the Digital Workplace

Paris, March 11, 2025 – eXo Platform, a leading open-source provider of intranet and digital…

3 weeks ago

Sasa Software Appoints Udi Doenyas as New Chairman of the Board

Tel Aviv, March 11, 2025 – Sasa Software, a global leader in advanced cybersecurity solutions…

3 weeks ago

Leaders, influencers, and individuals worldwide walk backwards to highlight the need to move forwards for women‘s rights.

Global Regression in Women's Rights Sparks UN Women National Committees’ 'March Forward' Campaign. Fri, Mar…

3 weeks ago

Savox Communications Initiates Cooperation Deal with a Northern European Customer for Advanced Audio and Intercom Command System

[Helsinki, Finland – March 7, 2025] – Savox Communications, a global leader in mission-critical communications…

4 weeks ago